
CLAIMS

1. A compound of formula **(II-h)**:



(II-h),

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:

R^1 is C_1-C_6 alkyl substituted with one more halo, -R^4OR^5;

each R^{2a} is hydrogen, C_1-C_6 alkyl, halo or C_1-C_6 haloalkyl; and

Y is phenyl substituted with one or more C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_8 cycloalkyl, halo, cyano, or -R^4OR^5;

R^4 is a bond, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; and

R^5 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof wherein:

each R^{2a} is hydrogen;

R^1 is C_1-C_6 alkyl substituted with one or more halo or -R^4OR^5;

Y is phenyl substituted with one or more C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_3-C_8 cycloalkyl, halo, cyano, or -R^4OR^5, wherein at least one substitution is substituted at the para-position of the phenyl ring;

R^4 is a bond; and

R^5 is hydrogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl.


3. The compound of any one of the preceding claims or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein **Y** is phenyl substituted with one, two or three of any of C_1-C_6 haloalkyl, halo, cyano, or -R^4OR^5.

4. The compound of claim 3 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein Y is phenyl substituted with one or two of any of C_1-C_6 haloalkyl, halo, cyano or -R^4OR^5.


5. The compound of any one of claims 1 or 2 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein Y is phenyl substituted with one or more halo or -R^4OR^5.

6. The compound of claim 2 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein the at least one substitution substituted at the para-position of the phenyl ring is chloro.

7. The compound of any one of the preceding claims or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein **R^1** is




, or .

8. The compound of any one of the preceding claims or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein **R^1** is 

.

9. The compound of any one of the preceding claims, wherein **R^5** is hydrogen.


10. The compound of claim 1 or 2, wherein the compound is of Formula (II-h):




(II-h),

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof; and

R^1 is



, or



;


each R^{2a} is hydrogen;

Y is phenyl substituted with one or more C_1-C_6 alkyl, C_1-C_6 haloalkyl, halo, or -R^4OR^5 and at least one substitution is substituted at the para-position of the phenyl ring;

R4 is absent, and

R5 is hydrogen.


11. The compound of claim 10 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein the compound is of Formula (**II-h**):




(**II-h**),

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof; and

R^1 is



, or



;

each R^{2a} is hydrogen;

Y is phenyl substituted with one, two or three of any of C_1-C_6 haloalkyl, halo, cyano or -R^4OR^5, and at least one substitution is substituted at the para-position of the phenyl ring;


R^4 is a bond; and

R^5 is hydrogen.

12. The compound of claim 10 or 11 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein Y is phenyl substituted with one or two of any of C_1-C_6 haloalkyl, halo, cyano or -R^4OR^5.

13. The compound of any one of claims 10 to 12 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein Y is phenyl substituted with two substituents.

14. The compound of claim 13 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein each substituent is selected from halo or -R^4OR^5.

15. The compound of any one of claims 10 to 14 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein **R^1** is 

.

16. The compound of claim 14 or 15 or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein halo is chloro.

17. A pharmaceutical composition comprising the compound of any one of the preceding claims or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, or tautomer thereof, and one or more pharmaceutically acceptable carriers.

18. The compound or composition of any one of the preceding claims, for use in treating or preventing an NLRP3-related disease or disorder selected from inflammation, an auto-immune disease, a cancer, an infection, a disease or disorder of the central nervous system, a metabolic disease, a cardiovascular disease, a respiratory disease, a kidney disease, such as acute kidney disease, chronic kidney disease, or a rare kidney disease, a liver disease, an ocular disease, a skin disease, a lymphatic disease, a rheumatic disease, a psychological disease, graft versus host disease, or allodynia.